News for ACADIA Pharmaceuticals Inc. (0A4W.L)

JP Morgan analyst Tessa Romero has updated her stance on ACADIA Pharmaceuticals (ACAD), maintaining an

Acadia Pharmaceuticals (ACAD) to announce Q2 2025 financial results on August 6, 2025. Conference call and webcast scheduled for the same day at 4:30 p.

Below is the June 2025 Monthly Update for the Liberty All-Star Growth Fund, Inc. (NYSE: ASG). Liberty All-Star Growth Fund, Inc. Ticker: ASG Monthly Update,

Taysha Gene Therapies (TSHA) is gaining attention after BofA analyst Tazeen Ahmad initiated coverage with a Buy rating and an $8 price target. The spotlight is

Summary ACADIA Pharmaceuticals Inc (ACAD) announced on July 2, 2025, that its Compensation Committee has granted inducement awards to seventeen new employees un

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on July 2, 2025, the Compensation Committee of Acadia's Board of Directors (the ”œCommittee”

Acadia Pharmaceuticals Inc. (ACAD) grants stock options and RSUs to new employees as part of its 2024 Inducement Plan. 35,607 stock options and 29,571 R

On June 26, 2025, Oppenheimer analyst Jay Olson announced an update regarding ACADIA Pharmaceuticals (ACAD), maintaining a "Perform" rating on the stock. The ra

JMP Securities has reiterated its "Market Outperform" rating for ACADIA Pharmaceuticals (ACAD), maintaining its previous price target of $37.00 USD. The decisio

ACADIA Pharmaceuticals (ACAD) continues to receive positive attention from analysts, as evidenced by HC Wainwright & Co.'s recent reiteration of their

On June 23, 2025, RBC Capital, led by analyst Brian Abrahams, announced an update on ACADIA Pharmaceuticals (ACAD). The firm has maintained its "Outperform" rat

On June 12, 2025, Baker Bros. Advisors LP executed a significant stock transaction involving Prelude Therapeutics Inc. The firm added 146,144 shares of Prelude

Summary ACADIA Pharmaceuticals Inc (ACAD) announced on June 6, 2025, that its Compensation Committee has granted inducement awards to 41 new employees under the

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on June 6, 2025, the Compensation Committee of Acadia's Board of Directors (the ”œCommittee”

Acadia Pharmaceuticals (ACAD) grants inducement stock options and RSUs to 41 new employees. The awards, under Nasdaq Rule 5635(c)(4), include 187,664 st

The FDA Commissioner Marty Makary stated the FDA will reach its 2025 drug approval targets despite severe workforce reductions.

Acadia Pharmaceuticals (ACAD) has received a favorable ruling from the Federal Court of Appeals, which upholds the validity of its '740 composition of matter pa

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Court of Appeals for the Federal Circuit affirmed a decision issued by the U.S. Distri

Summary: Acadia Pharmaceuticals (ACAD) successfully upholds its key patent in a significant legal victory. Analysts predict a potential 21.08% upside, wi